Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • May 12, 2011

165_ip_2011-05-12_d550dbb6-7c33-4c6e-b615-1f347e93992c.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Annual General Meeting of Fresenius Medical Care AG & Co. KGaA

Frankurt am Main | May 12, 2011 Dr. Ben Lipps, Chief Executive Officer and Chairman of the Management Board

Accomplishments and Business Update

Fiscal Year 2010 −Accomplishments

Record results for 2010

  • Record revenue of more than US\$12 billlion
  • Record net income of US\$979 million
  • Expanded our global market share
  • Very strong cash flow
  • Continued focus on quality, research and innovation
\$
S
U
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
1
0		 G
h
i
%
t
r
o
w
n
N
t
e
r
e
e
n
e
v
u		 1
2
0
3
5
,		 7
O
(
)
t
i
i
E
B
I
T
p
e
r
a
n
g
n
c
o
m
e		 1
9
2
4
,		 1
0
N
i
t
e
n
c
o
m
e		 9
9
7		 1
0

2010 -Excellent Revenue Growth in all Regions

cc = constant currency

Decade of Growth & Exceeded GOAL 10 Targets

CAGR = Compound annual growth rate

In US\$ million

We Created More Than 5,400 Jobs Worldwide

Success Requires Expertise and Continuity

Vertically integrated renal therapy provider

  • 30 years of complex manufacturing technology
  • Extensive quality management systems
  • Comprehensive patient care
  • Highly innovative product development

Years of expertise

  • Management Board with more than 150 years experience
  • Global staff averaging 20 years of service

Supervisory Board Continuity Contributes to Shareholder Value

FMC Supervisory Board 2000 FMC Supervisory Board 2010

Dr. Gerd Krick

Dr. Dieter Schenk

Dr. Walter L. Weisman

Prof. Dr. Bernd Fahrholz

Dr. Gerd Krick

Dr. Dieter Schenk

Dr. Walter L. Weisman

Prof. Dr. Bernd Fahrholz

Dr. Theo Spettmann John Gerhard Kringel

Stephen M. Peck William P. Johnston

Continue Long-term Incentive Plan

Share Repurchase Authorization

2010│2011 Expansion

Drivers for sustained revenue and earnings growth

  • Refinanced US\$1.1 billion of debt
  • Acquisition of Asia Renal Care with ~80 clinics
  • Acquisition of Gambro peritoneal dialysis business
  • Joint venture with Galenica
  • Acquisition of Euromedic's dialysis services business with ~70 clinics

2010│2011− Product Launches

Global Healthcare Reimbursement Reforms

Commitment to improve quality and lower cost

  • U.S. dialysis bundle prospective payment system effective January 1st, 2011
  • Portugal – bundled payment system
  • Spain – performance-based reimbursement system
  • USA –Integrated Care

Strong Balance Sheet

2010 Annual Dividend Proposal

2000 May 2011 | Share Price Development

Impressive decade - clearly outperformed the markets

Average Yearly Value Performance

Compound average growth rates 2000 - 2010

Raised full-year guidance based on positive Q1 results despite U.S. Medicare reimbursement reform

\$
S
U
i
i
l
l
i
n
m
o
n
s		 Q
1
2
0
1
0		 Q
1
2
0
1
1		 G
h
i
%
t
r
o
n
w
N
t
e
r
e
v
e
n
u
e		 2
8
8
2
,		 3
0
3
6
,		 5
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
2
5		 4
4
5		 5
N
i
t
e
n
c
o
m
e		 2
1
1		 2
2
1		 5

Strong underlying operating performance

Growth Strategy and Summary

Market Position by Major Product Groups 2010

R
k
1
a
n		 R
k
2
a
n
D
i
l
a
y
z
e
r
s		 F
M
E		 G
b
a
m
r
o
D
i
l
i
h
i
a
y
s
s
m
a
c
n
e
s		 F
M
E		 G
b
a
m
r
o
H
d
i
l
i
t
t
e
m
o
a
y
s
s
c
o
n
c
e
n
r
a
e
s		 F
M
E		 F
u
s
o
B
l
d
l
i
o
o
n
e
s		 F
M
E		 G
b
a
m
r
o
P
i
l
d
i
l
i
d
t
t
e
r
o
n
e
a
a
s
s
p
r
o
c
s
y
u		 B
t
a
e
r
x		 F
M
E

Produced ~92,000,000 dialyzers in 2010

World Leader in Dialysis Services*

We lead in every major market, Treating more than 216,000 patients worldwide

  • * Based on company statements and estimates
  • * * Patients including managed clinics for fullyear 2010 20

Development of Dialysis Patient Population

Estimates suggest an increase to nearly 4 million dialysis patients in 2020

Market Opportunity by Region (Data in US\$ Billions)

Strong revenue growth and further earnings momentum expected

\$
U
S
i
i
l
l
i
n
m
o
n
s		 O
t
l
k
F
b
2
0
1
1
o
o
e
u		 F
Y
2
0
1
1
N
E
W
N
t
e
r
e
e
n
e
v
u		 1
2
8
0
0
1
3
0
0
0
–
,
,		 1
3
0
0
0
>
,
N
t
i
e
n
c
o
m
e
i
b
b
l
F
M
C
A
G
&
C
K
G
A
t
t
t
t
a
r
u
a
e
o
o.
a		 1
0
3
1
0
5
5
5
–
,
,		 1
0
0
1
0
9
0
7
–
,
,

Summary

Leadership

  • Maintain global leadership position
  • Continue to shape the future of the dialysis industry

Quality

• Continue to focus on superior quality in services and products

Growth

  • Take opportunity of international growth potential
  • Continue horizontal expansion of service and product range
  • Benefit from product innovations and new product launches

Financials

  • Maintain cost control and continue profitable growth momentum
  • Seek attractive investment opportunity

Thank you for your interest and support of Fresenius Medical Care

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.